Peptides that inactivate the novel coronavirus

A peptide that binds to the HR2 domain of SARS-CoV-2's spike protein forms an α-helix to inhibit viral infectivity, addressing vaccine resistance and variant challenges, offering broad-spectrum efficacy against SARS-CoV-2 strains.

JP2026182192APending Publication Date: 2026-11-19KOBE UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2025078209
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2025-05-08
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing COVID-19 vaccines and therapies face challenges with drug-resistant mutations and decreased effectiveness against SARS-CoV-2 variants, necessitating a peptide that can inhibit the virus's infectivity by targeting the HR2 domain, which has fewer mutations.

Method used

A peptide or its salt that binds to the HR2 domain of the S2 region of the SARS-CoV-2 spike protein, forming an α-helix through hydrophobic interactions, inhibiting the formation of helix bundles and reducing viral infectivity.

Benefits of technology

The peptide effectively inactivates SARS-CoV-2, including variants, by targeting the conserved HR2 domain, providing therapeutic potential against current and future strains.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026182192000010
    Figure 2026182192000010
  • Figure 2026182192000011
    Figure 2026182192000011
  • Figure 2026182192000012
    Figure 2026182192000012
Patent Text Reader

Abstract

To provide a peptide that inactivates the novel coronavirus. [Solution] A peptide or salt thereof that binds to the HR2 domain in the S2 region of the spike protein of the novel coronavirus SARS-CoV-2, wherein the number of amino acid residues is 50 or less; a novel coronavirus infection inhibitor containing the peptide or salt thereof; and a composition for the treatment of novel coronavirus infection containing the peptide or salt thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This invention relates to a peptide that inactivates the novel coronavirus. [Background technology]

[0002] COVID-19 is caused by the novel coronavirus (Severe acute respiratory syndrome coronavirus 2: SARS-CoV-2). SARS-CoV-2 has numerous spike proteins (also called "s proteins" or "spike glycoproteins") on its surface, with the N-terminal region (up to 685 residues) called the S1 region and the C-terminal region (686-1273 residues) called the S2 region. The S1 region binds to human cells and plays a crucial role in infection, while the S2 region is inserted into the viral membrane and contains elements necessary for membrane fusion. When the S1 region binds to a human cell, the HR1 and HR2 domains within the S2 region combine to form a six-helix bundle. This initiates membrane fusion, allowing the virus to infect human cells.

[0003] To date, over 700 million people have been infected with SARS-CoV-2, and more than 7 million have died. Currently, vaccines and therapies that inhibit the virus's replication cycle have been developed, approved, and are in clinical use. However, the emergence of drug-resistant mutations and decreased vaccine effectiveness against variants have already occurred, making the ease with which variants can develop a challenge in drug discovery.

[0004] It has been shown that inhibiting the binding of domains within the S2 region can reduce the infectivity of the virus. For example, Non-Patent Literature 1 reported that CoVS-HR1, a single-chain chimeric protein that mimics the coiled-coil structure of the S2 HR1 trimer of SARS-CoV-2, binds to HR2 and exhibits inhibitory activity against wild-type and Omicron strains of SARS-CoV-2. Furthermore, Non-Patent Literature 2 reported that recombinant protein HR121, which has a structure of HR1, HR2, and a linked HR1 in the S2 region of SARS-CoV-2, binds to HR2, functions as a fusion inhibitor, and exhibits neutralizing activity against wild-type and major mutants of SARS-CoV-2. [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] Int J Biol Macromol. 2022 Oct 8;222:2467-2478 [Non-Patent Document 2] Acta Pharm Sin B. 2023 May 26;13(8):3339-3351 [Overview of the Initiative] [Problems that the invention aims to solve]

[0006] A comparison of SARS-CoV-2 variants observed to date revealed that very few mutations have occurred in the S2 region. This invention aims to develop a peptide that prevents infection by SARS-CoV-2, including variants, by binding to the HR2 domain, which has shown very few mutations to date, and inhibiting the formation of helix bundles.

[0007] The object of this invention is to provide a peptide that inactivates SARS-CoV-2. [Means for solving the problem]

[0008] To solve the above problems, the present invention includes the following inventions. [1] A peptide or salt thereof that binds to the HR2 domain in the S2 region of the spike protein of the novel coronavirus SARS-CoV-2, wherein the number of amino acid residues is 50 or less. [2] The peptide or salt thereof described in [1], which targets the region containing the amino acid sequence NIQKEIDRLNEVAKNLNESL (Sequence ID 2) at positions 1178 to 1197 of the amino acid sequence of Sequence ID 1. [3] A peptide or salt thereof that forms an α-helix, as described in [1]. [4] The peptide or a salt thereof described in [1], which binds to the HR domain by hydrophobic interaction. [5] The peptide according to [1] or a salt thereof, comprising an amino acid sequence represented by the following formula (I) or (II): (I)ALREQLERLLRQLQELX1RX2L(Sequence ID 3) (II)ALREQLERLLRQLQELX1RX2LRELQR (Sequence ID 4) (Either X1 and X2 are positively charged amino acids, or X1 and X2 are a combination of homogeneous or heterogeneous uncharged amino acids.) [6] The peptide according to [5] or a salt thereof, wherein the peptide comprises any of the following amino acid sequences (1) to (4). (1)ALREQLERLLRQLQELERKL(Sequence ID 5) (2)ALREQLERLLRQLQELQRNL(Sequence ID 6) (3)ALREQLERLLRQLQELERKLRELQR (Sequence ID 7) (4)ALREQLERLLRQLQELQRNLRELQR(Sequence ID 8) [7] The peptide according to [6] or a salt thereof, wherein the peptide comprises any of the following amino acid sequences (1w) to (4w). (1w)ALREQLERLLRQLQELERKLW (Sequence ID 9) (2w) ALREQLERLLRQLQELQRNLW (SEQ ID NO: 10) (3w) ALREQLERLLRQLQELERKLRELQRW (SEQ ID NO: 11) (4w) ALREQLERLLRQLQELQRNLRELQRW (SEQ ID NO: 12) An inhibitor of novel coronavirus infection comprising the peptide according to any one of [1] to [7] or a salt thereof. A composition for treating novel coronavirus infectious disease, comprising the peptide according to any one of [1] to [7] or a salt thereof. [Advantageous Effects of Invention]

[0009] According to the present invention, a peptide that inactivates SARS-CoV-2 can be provided. According to the present invention, a therapeutic agent that is effective even against variants of the novel coronavirus can be provided. [Brief Description of the Drawings]

[0010] [Figure 1] It is a diagram showing the full amino acid sequence of the spike protein of the novel coronavirus SARS-CoV-2 (SEQ ID NO: 1), together with the positions of its S2 region, HR1 domain and HR2 domain, as well as the amino acid sequences of the target regions of four types of ACP (ACP21_EK, ACP21_QN, ACP26_EK and ACP26_QN) (SEQ ID NO: 2). [Figure 2] It is a helical wheel diagram of positions 1178 to 1197 of the target region within the HR2 domain. [Figure 3] For the HR2 peptide, they are a graph (A) showing the results of CD measurement performed by varying the ethanol concentration in the measurement sample, and a graph (B) showing the relationship between the ethanol ratio and the helix content. [Figure 4] It is a graph showing CD spectra at room temperature (25°C) for four types of ACP (ACP21_EK, ACP21_QN, ACP26_EK and ACP26_QN). [Figure 5-1]This graph shows the CD spectra for ACP21_EK and ACP21_QN, measured at temperatures ranging from 0 to 95°C. [Figure 5-2] This graph shows the CD spectra of ACP26_EK and ACP26_QN measured at temperatures ranging from 0 to 95°C. [Figure 6] This graph shows the CD spectra of four types of ACP peptides, measured at temperatures ranging from 0 to 95°C, plotted as a function of the CD spectrum value at 222 nm ([θ]222nm) against temperature. [Figure 7-1] This is a spectral diagram of the mixture spectrum and difference spectrum for ACP21_EK. [Figure 7-2] This is a spectral diagram of the mixture spectrum and difference spectrum for ACP21_QN. [Figure 7-3] This is a spectral diagram of the mixture spectrum and difference spectrum for ACP26_EK. [Figure 7-4] This is a spectral diagram of the mixture spectrum and difference spectrum for ACP26_QN. [Figure 8A] This is a mass spectrum diagram of ACP21_QN obtained by electrospray ionization mass spectrometry (ESI-MS) using infusion. [Figure 8B] This is a mass spectrum diagram of ACP26_EK, obtained from electrospray ionization mass spectrometry (ESI-MS) performed by infusion. [Figure 9] This figure shows the three-dimensional structure of the peptide visualized by structural analysis based on molecular dynamics calculations ((a) shows the interaction structure of the HR2 domain excised from the native spike protein (HR2+ACP0), and (b) shows the structure after the interaction between HR2 and ACP21_EK (HR2_W+ACP21_EK_W)). [Modes for carrying out the invention]

[0011] 〔peptide〕 This invention provides a peptide that binds to the HR2 domain within the S2 region of the spike protein of the novel coronavirus SARS-CoV-2.

[0012] In this specification, the term "peptide" refers to a molecule composed of multiple amino acids linked by peptide bonds. In this specification, amino acids may be represented by commonly known three-letter or one-letter abbreviations. Furthermore, amino acid sequences are shown from left to right, from the amino terminus (N-terminus) to the carboxyl terminus (C-terminus).

[0013] In this specification, "HR2 domain-binding peptide" means a peptide having the property or ability to bind to the HR2 domain. The peptides of the present invention can bind to the HR2 domain or a peptide having a structure similar to the HR2 domain when they come into contact with the HR2 domain or a peptide having a structure similar to the HR2 domain. Therefore, in this specification, unless otherwise specified, "HR2 domain" means either the HR2 domain of the SARS-CoV-2 spike protein or a peptide having a structure similar to the HR2 domain. In this specification, the peptides described above are also referred to as "HR2-binding peptides."

[0014] The full-length amino acid sequence of the SARS-CoV-2 spike protein is shown, for example, in NCBI Reference Sequence: YP_009724390.1, and this amino acid sequence (SEQ ID NO: 1) is shown in Figure 1. The S2 region is the C-terminal region of the spike protein, i.e., the region consisting of amino acid residues from positions 686 to 1273. The S2 region contains the HR1 domain and the HR2 domain. In this specification, the HR1 domain is the region consisting of amino acid residues from positions 912 to 984 of the spike protein, and the HR2 domain is the region consisting of amino acid residues from positions 1163 to 1213 of the spike protein (in Figure 1, these domains are shown as shaded areas). The HR2 domain can adopt an α-helix structure in the environment near the viral membrane. Furthermore, when SARS-CoV-2 infects cells, the HR2 domain can bind to the α-helix structure of the HR1 domain in an α-helix structure.

[0015] In this specification, "binding to the HR2 domain" does not mean binding only to the entire HR2 domain (the entire region consisting of residues 1163 to 1213), but may also mean binding to a portion of the HR2 domain. The lower limit of the number of amino acid residues constituting a "portion of the HR2 domain" is, for example, 17 or more, preferably 18 or more, more preferably 19 or more, and even more preferably 20 or more, and the upper limit is not particularly limited as long as it is less than or equal to the number of amino acid residues constituting the entire HR2 domain.

[0016] The HR2-binding peptide of the present invention preferably targets the region containing the amino acid sequence NIQKEIDRLNEVAKNLNESL (Sequence ID 2) from positions 1178 to 1197 of Sequence ID 1 (the amino acid sequence of the entire spike protein). The target region is located in the HR2 domain (Figure 1) and can take the form of an α-helix structure (Figure 2). Figure 2 is a helical wheel diagram of the target region. In Figure 2, hydrophobic residues are represented by enclosed amino acids. As shown in Figure 2, in the target region, hydrophobic residues (e.g., leucine (Leu,L), isoleucine (Ile,I), alanine (Ala,A), and valine (Val,V)) can be concentrated on one side of the α-helix.

[0017] The HR2-binding peptide of the present invention has 50 or fewer amino acid residues. The length of the HR2-binding peptide of the present invention is not limited as long as it has 50 amino acids or less and can bind to the HR2 domain. Preferably, the lower limit of the number of amino acid residues is 17, more preferably 18, even more preferably 19, and still more preferably 20. The upper limit of the number of amino acid residues can be any number up to 50 (however, it must be a number greater than the lower limit). Preferably, the upper limit of the number of amino acid residues is 42, more preferably 35, and even more preferably 28.

[0018] The HR2-binding peptide of the present invention can form an α-helix and can adopt an α-helix structure. For example, the ability of the peptide to form an α-helix can be confirmed by structural prediction using protein structure prediction tools such as AlphaFold2 and ColabFold. Furthermore, the secondary structure of the HR2-binding peptide can be confirmed, for example, by CD (circular dichroism) measurement. The HR2-binding peptide can adopt an α-helix structure in its unbound state (before binding to the HR2 domain). In its unbound state, the HR2-binding peptide can form an α-helix with a helix content of, for example, 20% or more, preferably 50-95%, depending on the solvent conditions. The helix content is calculated, for example, by performing CD measurement using a 50 μM test peptide and 20 mM phosphate buffer (pH 7.0) or a 25 μM test peptide without phosphate buffer as the measurement sample, under the following conditions: temperature 25°C, scanning wavelength 250 nm to 190 nm, data interval 0.2 nm, scanning speed 100 nm / min, response 2 seconds, bandwidth 1 nm, sensitivity 10 mdeg, and 8 integrations, and using the CD spectral value at 222 nm, using the following formula.

[0019]

number

[0020] Furthermore, HR2-binding peptides can adopt an α-helix structure when bound to the HR2 domain. The secondary structure of HR2-binding peptides in the bound state to the HR2 domain can be confirmed, for example, by CD measurement. In addition, the three-dimensional structure of the interaction or binding of the HR2-binding peptide to the HR2 domain can be confirmed by structural analysis based on molecular dynamics calculations ("MD calculations"). When bound to the HR2 domain, HR2-binding peptides can form an α-helix with a helix content of, for example, 80% or more, preferably 80-105%. The helix content is calculated, for example, using a 222 nm CD spectrum measured under the same measurement conditions as above, except that a 50 μM test peptide, 20 mM phosphate buffer (pH 7.0), and 50% (v / v) ethanol sample is used for CD measurement.

[0021] The HR2-binding peptide of the present invention can bind to the HR2 domain via hydrophobic interactions. The HR2 domain contains hydrophobic amino acid residues. Preferably, the HR2-binding peptide of the present invention contains at least one hydrophobic amino acid residue, and its target region also contains at least one hydrophobic amino acid residue. Examples of hydrophobic amino acid residues include alanine (Ala,A), valine (Val,V), leucine (Leu,L), isoleucine (Ile,I), phenylalanine (Phe,F), methionine (Met,M), and tryptophan (Trp,W). Hydrophobic interactions can occur between hydrophobic amino acid residues of the HR2-binding peptide and hydrophobic amino acid residues within the HR2 domain. Through these hydrophobic interactions, the HR2-binding peptide of the present invention can bind to the HR2 domain and function while maintaining its α-helix structure.

[0022] The HR2-binding peptide of the present invention preferably has a positive net charge at pH 7.0. This facilitates interaction with negatively charged cell membranes. The net charge at pH 7.0 can be theoretically calculated using the dissociation constant of the amino acid side chain. From the viewpoint of cytotoxicity, a net charge of +2 or less at pH 7.0 is more preferable.

[0023] The HR2-binding peptide of the present invention may be designed based on the information disclosed herein by designing a sequence that forms an α-helix and selecting amino acid residues that create hydrophobic interactions with the target region.

[0024] The HR2-binding peptide of the present invention may have additional amino acid residues added, provided that the binding to the HR2 domain is not impaired (however, the number of amino acid residues does not exceed 50). For example, amino acid residues may be added to stabilize the three-dimensional structure of the HR2-binding peptide. In addition, amino acid residues may be added as needed for confirmation experiments of the HR2-binding peptide. For example, as shown in the examples below, tryptophan (Trp,W) can be added to the C-terminus to facilitate the measurement of the peptide concentration.

[0025] In one embodiment, the HR2-binding peptide of the present invention comprises an amino acid sequence represented by the following formula (I) or (II): (I)ALREQLERLLRQLQELX1RX2L(Sequence ID 3) (II)ALREQLERLLRQLQELX1RX2LRELQR (Sequence ID 4) (Either X1 and X2 are positively charged amino acids and the other is negatively charged amino acids, or X1 and X2 are a combination of the same or different uncharged amino acids (preferably hydrophilic amino acids)). Positively charged amino acids are amino acids with a positive charge in their side chains, such as lysine (Lys,K), arginine (Arg,R), and histidine (His,H). Negatively charged amino acids are amino acids with a negative charge in their side chains, such as aspartic acid (Asp,D) and glutamic acid (Glu,E). For example, X1 may be a negatively charged amino acid and X2 a positively charged amino acid, but the reverse is also possible. Any combination of positively charged and negatively charged amino acids is possible. Uncharged amino acids are amino acids that do not have an electric charge in their side chains, and may be hydrophilic amino acids (e.g., serine (Ser,S), threonine (Thr,T), cysteine ​​(Cys,C), tyrosine (Tyr,Y), asparagine (Asn,N), glutamine (Gln,Q), or glycine (Gly,G)) or hydrophobic amino acids (e.g., alanine (Ala,A), valine (Val,V), leucine (Leu,L), isoleucine (Ile,I), phenylalanine (Phe,F), tyrosine (Tyr,Y), tryptophan (Trp,W), or methionine (Met,M)). When X1 and X2 are uncharged amino acids, they are preferably the same or different hydrophilic amino acid residues.

[0026] In one embodiment, in formula (I) or (II), X1 is glutamic acid (Glu,E) and X2 is lysine (Lys,K), and in another embodiment, X1 is glutamine (Gln,Q) and X2 is asparagine (Asn,N). In these embodiments, the HR2-binding peptide of the present invention comprises any of the following amino acid sequences (1) to (4): (1)ALREQLERLLRQLQELERKL(Sequence ID 5) (2)ALREQLERLLRQLQELQRNL(Sequence ID 6) (3)ALREQLERLLRQLQELERKLRELQR (Sequence ID 7) (4)ALREQLERLLRQLQELQRNLRELQR(Sequence ID 8)

[0027] Furthermore, the HR2-binding peptide of the present invention may consist of any of the following amino acid sequences (1w) to (4w): (1w)ALREQLERLLRQLQELERKLW (Sequence ID 9) (2w)ALREQLERLLRQLQELQRNLW(Sequence ID 10) (3w)ALREQLERLLRQLQELERKLRELQRW (Sequence ID 11) (4w)ALREQLERLLRQLQELQRNLRELQRW (Sequence ID 12) The amino acid sequences (1w) to (4w) above are obtained by adding tryptophan (Trp,W) to the C-terminus of the amino acid sequences (1) to (4) above.

[0028] The HR2-binding peptide of the present invention has infection inhibitory activity against SARS-CoV-2. The HR2-binding peptide of the present invention can bind to the HR2 domain of the SARS-CoV-2 spike protein and form a complex with the HR2 domain. This inhibits trimer formation of the HR2 domain or binding of the HR2 domain to the HR1 domain, thereby inhibiting the formation of the six-helix bundle and membrane fusion, and thus reducing or eliminating the infectivity of SARS-CoV-2. The peptide of the present invention can also be called a peptide that inactivates the novel coronavirus (SARS-CoV-2) or an anti-coronavirus peptide (ACP).

[0029] The SARS-CoV-2 infection inhibitory activity of HR2-binding peptides can be confirmed using SARS-CoV-2 infection inhibition tests known to those skilled in the art. Examples include cell culture experiments (adding the inhibitor to cultured cells infected with the virus and observing viral proliferation), animal model experiments (administering the inhibitor to experimental animals infected with the virus and observing the viral infection inhibitory effect by pathological dissection of the lungs or measurement of viral RNA), and binding inhibition assays (using an assay kit to search for substances that inhibit the binding of the viral spike protein to the cell receptor (ACE2), and measuring the binding activity of ACE2 in the presence of the inhibitor using a colorimetric method). The SARS-CoV-2 infection inhibitory activity of HR2-binding peptides can be confirmed, for example, using the method described in Example 4 below.

[0030] The HR2-binding peptide of the present invention can be used as a SARS-CoV-2 infection inhibitor due to its infection-inhibiting activity against SARS-CoV-2. The HR2-binding peptide of the present invention can be used as an active ingredient in therapeutic compositions for COVID-19. Furthermore, the HR2-binding peptide of the present invention can be used as a component of pharmaceuticals.

[0031] The HR2-binding peptide of the present invention can be produced by solid-phase synthesis (Fmoc method, Boc method) or liquid-phase synthesis according to known general peptide synthesis protocols. Alternatively, it can be produced by a transformant introduced with an expression vector containing the DNA encoding the peptide of the present invention, or by an in vitro transcription and translation system.

[0032] The HR2-binding peptide of the present invention has a carboxyl group (-COOH) at the C-terminus and a carboxylate group (-COOH). - ), it may be any of the amide group (-CONH2) or ester group (-COOR). Preferably it is the amide group (-CONH2). For R in the ester group, for example, C may be a methyl group, ethyl group, n-propyl group, isopropyl group or n-butyl group. 1-6Alkyl groups, for example, C such as cyclopentyl group, cyclohexyl group, etc. 3-8 Cycloalkyl groups, for example, C such as phenyl group, α-naphthyl group, etc. 6-12 Aryl groups, for example, phenyl-C such as benzyl group, phenethyl group, etc. 1-2 α-naphthyl-C such as alkyl group or α-naphthylmethyl group, etc. 1-2 C such as alkyl group, etc. 7-14 In addition to aralkyl groups, commonly used oral ester groups such as pivaloyloxymethyl group and the like can be mentioned. When the peptide of the present invention has a carboxy group or a carboxylate group at a position other than the C-terminus, those in which these groups are amidated or esterified are also included in the peptide of the present invention.

[0033] The amino acids constituting the HR2-binding peptide of the present invention may have side chains modified with any optional substituent. The substituent is not particularly limited, and examples thereof include a fluorine atom, a chlorine atom, a cyano group, a hydroxyl group, a nitro group, an alkyl group, a cycloalkyl group, an alkoxy group, and an amino group.

[0034] Furthermore, the HR2-binding peptide of the present invention includes those in which the amino group of the N-terminal amino acid residue is protected with a protecting group (for example, formyl group, C such as acetyl, etc. 2-6 C such as alkanoyl group, etc. 1-6 acyl group, etc.), those in which the glutamyl group generated by in vivo cleavage at the N-terminal side is pyroglutamylated, and those in which the substituent on the side chain of an intramolecular amino acid (for example, -OH, -SH, amino group, imidazole group, indole group, guanidino group, etc.) is protected with an appropriate protecting group (for example, C such as formyl group, acetyl group, etc. 2-6 C such as alkanoyl group, etc. 1-6 acyl group, etc.) are also included.

[0035] The HR2-binding peptides of the present invention may form salts or hydrates thereof. Pharmaceutically acceptable salts are preferred. Specifically, examples include salts with acids such as hydrochloric acid, sulfuric acid, phosphoric acid, lactic acid, tartaric acid, maleic acid, fumaric acid, oxalic acid, malic acid, citric acid, oleic acid, and palmitic acid; salts with alkali metals or alkaline earth metals such as sodium, potassium, and calcium, or with aluminum hydroxides or carbonates; and salts with triethylamine, benzylamine, diethanolamine, t-butylamine, dicyclohexylamine, arginine, etc. The term "peptide or its salt" includes salts of peptides (preferably pharmaceutically acceptable salts) and hydrates of peptides or peptide salts.

[0036] The HR2-binding peptide of the present invention may contain D-amino acids or non-natural amino acids, as long as the properties of the original peptide are preserved. Furthermore, other substances may be linked to the peptide, as long as the properties of the original peptide are preserved. Examples of other substances that can be linked to the peptide include other peptides, lipids, sugars or glycans, acetyl groups, natural or synthetic polymers, etc. Additionally, the peptide of the present invention may be modified by means of glycosylation, side-chain oxidation, phosphorylation, etc., as long as the properties of the original peptide are preserved.

[0037] [COVID-19 Inhibitors] The present invention provides a novel coronavirus infection inhibitor (also referred to herein as "infection inhibitor"). The infection inhibitor of the present invention contains an HR2-binding peptide (ACP) or a salt thereof as an active ingredient. The infection inhibitor of the present invention can be used in vitro by addition to cells and in vivo by administration to animals in the presence of SARS-CoV-2 and its variants.

[0038] Because HR2-binding peptides (ACPs) target the HR2 domain within the S2 region, which is largely unmutated, they can target any SARS-CoV-2 strain without limitation. The infection inhibitors of the present invention can target wild-type and mutant strains (e.g., alpha strain (B.1.1.7), beta strain (B.1.351), gamma strain (P.1), delta strain (B.1.617.2), omicron strain (B.1.1.529) and its derivatives (e.g., XBB strain and EG strain)). In addition to existing mutants, the infection inhibitors of the present invention can also be effective against mutants that may arise in the future.

[0039] [Composition for the treatment of COVID-19] The present invention also provides a therapeutic composition for COVID-19 (hereinafter also referred to as "therapeutic composition"). The therapeutic composition of the present invention contains HR2-binding peptide (ACP) or a salt thereof as an active ingredient. COVID-19 refers to the symptoms caused by infection of a living organism with the wild-type or variant of the novel coronavirus SARS-CoV-2. The therapeutic composition of the present invention can be used as a pharmaceutical.

[0040] The therapeutic compositions of the present invention can be formulated by conventional methods, but are not limited to these. The therapeutic compositions of the present invention may be in any form: oral, topical, or injectable.

[0041] In the present invention, the dosage form when the product is formulated is not particularly limited. The therapeutic composition of the present invention can be formulated, for example, into tablets, coated tablets, pills, powders, granules, capsules, liquids, suspensions, emulsions, injections, infusions, suppositories, ointments, creams, gels, lotions, sticks, sprays, and transdermal patches (poultices, tapes, patches, etc.).

[0042] The therapeutic composition of the present invention can be formulated by appropriately blending the active ingredient with carriers or additives acceptable for the above-mentioned product. The blending ratio of the carriers or additives should be appropriately set based on the range commonly used in the field of the above-mentioned product. There are no particular limitations on the carriers or additives that can be blended, but examples include various carriers such as water, physiological saline, other aqueous solvents, aqueous or oily bases; and various additives such as excipients, binders, pH adjusters, disintegrants, absorption enhancers, lubricants, stabilizers, emulsifiers, surfactants, preservatives, antioxidants, colorants, flavoring agents, and fragrances. Furthermore, the therapeutic composition of the present invention can be formulated by conventional methods by blending components commonly used as raw materials for pharmaceuticals.

[0043] The therapeutic composition of the present invention is not limited to the target of administration. The therapeutic composition of the present invention can be administered to animals (for example, humans and other mammals (for example, rats, mice, rabbits, sheep, pigs, cattle, cattle, dogs, monkeys, etc.)). The method of administration may be either oral or parenteral administration. Parenteral administration includes, but is not limited to, transdermal administration, subcutaneous injection, intramuscular injection, intravenous injection, intraperitoneal injection, and local administration.

[0044] The dosage, when administered orally, is generally about 0.1 to 100 mg per day, preferably about 1.0 to 50 mg, and more preferably about 1.0 to 20 mg, for a person weighing about 60 kg. When administered parenterally, for example, in the case of an injectable preparation, the dosage is generally about 0.01 to 30 mg per day, preferably about 0.1 to 20 mg, and more preferably about 0.1 to 10 mg, for a person weighing about 60 kg, administered intravenously. However, this is not limited to these values, and the dosage may vary depending on the formulation method, the age, sex, symptoms, and method of administration of the recipient. The total daily dose may be a single dose or divided doses.

[0045] The present invention also includes the following inventions. A method for treating COVID-19, characterized by administering an effective amount of the peptide or a salt thereof of the present invention to an animal. Use of the peptide or a salt thereof of the present invention for the manufacture of a pharmaceutical product for the treatment of COVID-19. The peptide or a salt thereof of the present invention for use in the treatment of COVID-19. [Examples]

[0046] The present invention will be described in detail below with reference to examples, but the present invention is not limited to these examples.

[0047] [Example 1: Design and Synthesis of ACP]

[0048] [Table 1]

[0049] The five peptides shown in Table 1 were synthesized. The synthesis was performed using the F-moc solid-phase method.

[0050] The four types of ACPs (Anti-Coronavirus Peptides) in Table 1 were designed to target the amino acid region between positions 1178 and 1197 of the SARS-CoV-2 spike protein (SEQ ID NO: 1). This target region is located within the HR2 domain of the S2 region of the spike protein (Figure 1). Figure 2 shows a helical wheel diagram of this target region within the HR2 domain. In Figure 2, hydrophobic residues are represented by the enclosed amino acids. The peptides were designed to target hydrophobic interactions with hydrophobic residues (leucine (Leu,L), isoleucine (Ile,I), alanine (Ala,A), and valine (Val,V)) concentrated on one side of the α-helix of the target region. ACP21_EK and ACP21_QN consist of 21 amino acids, and ACP26_EK and ACP26_QN consist of 26 amino acids, each being a 5-amino acid extension in the C-terminal region of the 21-amino acid peptide. "_EK" and "_QN" represent the 17th and 19th amino acids of the peptide. The peptide with "_EK" contains the negatively charged amino acid glutamic acid (Glu,E) at the 17th position and the positively charged amino acid lysine (Lys,K) at the 19th position, while the peptide with "_QN" contains the uncharged amino acids glutamine (Gln,Q) and asparagine (Asn,N) at the 17th and 19th positions, respectively.

[0051] The HR2 peptide shown in Table 1 was designed as a peptide containing the amino acid sequence of the target region.

[0052] All synthetic peptides had tryptophan (Trp,W) added to their C-terminus to facilitate concentration measurement. The net charge of the peptides (pH 7.0) was theoretically calculated from the acid dissociation constants of each amino acid side chain.

[0053] [Example 2: Analysis of the three-dimensional structure and stability of the peptide] (1) Structural study of HR2 peptide The CD spectrum of the HR2 peptide synthesized in Example 1 was measured under the following conditions. The CD measurement sample consisted of: 50 μM test peptide, 20 mM phosphate buffer (pH 7.0), and ethanol from 0 to 80% (v / v) (varied in 10% (v / v) intervals). A Jasco J-720 spectro-polarimeter (manufactured by JASCO Corporation) was used for the measurement, and a 300 μL peptide solution was measured using a quartz cell with a path length of 1 mm. The measurement conditions were: temperature 25°C, scanning wavelength 250 nm to 190 nm, data interval 0.2 nm, scanning speed 100 nm / min, response 2 seconds, bandwidth 1 nm, sensitivity 10 mdeg, and number of integrations 8 times.

[0054] Furthermore, the peptide helix content (f) at each ethanol ratio H The following formula was used to calculate the value of the CD spectrum at 222 nm.

[0055]

number

[0056] Figure 3 shows graphs (A) and (B) of the CD measurement results for the HR2 peptide, performed by varying the ethanol concentration in the measurement sample. Figure 3B shows the maximum (max) and minimum (min) values ​​of the helix content, and the ethanol concentration (f) at which the helix content is halved. H50 A table showing the ), and the cooperativity index (n) is also provided. The results confirmed that the HR2 peptide cooperatively forms an α-helix structure upon the addition of ethanol. Furthermore, the addition of ethanol allowed us to reproduce the three-dimensional structure of the HR2 domain in the environment near the viral membrane.

[0057] (2) Three-dimensional structure study of ACP For the four ACPs synthesized in Example 1 (ACP21_EK, ACP21_QN, ACP26_EK, and ACP26_QN), the CD spectra were measured in the same manner as in Example 2(1), except that the CD measurement sample consisted of 50 μM test peptide and 20 mM phosphate buffer (pH 7.0). The results, i.e., the CD spectra of the four ACPs (ACP21_EK, ACP21_QN, ACP26_EK, and ACP26_QN) at room temperature (25°C), are shown in Figure 4. Negative peaks were observed at 208 nm and 222 nm for all four types, confirming the formation of an α-helix structure.

[0058] Furthermore, the ratio of the CD spectral value at 222 nm to the CD spectral value at 208 nm for each peptide ([θ] 222nm / [θ] 208nm The result was calculated. This result is shown in Table 2 below.

[0059] [Table 2]

[0060] From the results in Table 2, among them ACP21_EK, ACP21_QN, and ACP26_QN are [θ] 222nm / [θ] 208nm Because the value was large, it was presumed that it was bundled.

[0061] The helix content (%) was determined using the 222 nm CD spectrum value of each peptide. The results are shown in Table 3 below.

[0062] [Table 3]

[0063] (3) Examination of the structural stability of ACP by temperature change CD measurement Except for changing the composition of the CD measurement sample to a 25 μM test peptide without phosphate buffer and varying the measurement temperature from 0 to 95°C, the CD spectra of four types of ACP were measured in the same manner as in Example 2(1) above. The results are shown in Figure 5 (Figure 5-1: ACP21_EK and ACP21_QN; Figure 5-2: ACP26_EK and ACP26_QN). Furthermore, the CD spectrum values ​​at 222 nm as a function of temperature ([θ]) were obtained from these results. 222nm This was represented as a plot. The results are shown in Figure 6.

[0064] Also, the CD spectrum value at 222 nm ([θ] 222nm The enthalpy change ΔHm and the denaturation temperature (melting temperature) Tm were calculated from the given data. The results are shown in Table 4 below.

[0065] [Table 4]

[0066] CD measurements revealed that α-helix formation was particularly pronounced at low temperatures (below 25°C) for the four peptides, and the α-helix collapsed with increasing temperature (Figures 5 and 6). The α-helix was still maintained around 37°C, but the α-helix structure was not observed at higher temperatures. Furthermore, the ΔHm and Tm results shown in Table 4 confirmed that the extension of 5 amino acids contributed to α-helix formation, resulting in structural stabilization, and that the electrostatic interaction between the negative charge of glutamic acid (Glu,E) and the positive charge of lysine (Lys,K) further stabilized the α-helix structure.

[0067] [Example 3: Evaluation of the interaction of ACP with HR2] (1) CD measurement For four types of ACP (ACP21_EK, ACP21_QN, ACP26_EK, and ACP26_QN), the CD spectra of mixtures of each ACP with HR2 peptide were measured to investigate their interaction with HR2. Samples were prepared using 50 μM of the test peptide, 20 mM phosphate buffer (pH 7.0), and 50% (v / v) ethanol. The test peptides used were ACP alone, HR2 peptide alone, and peptide mixtures. For the peptide mixtures, 1 to 4 equivalents of ACP were added to the HR2 peptide. The CD spectra were measured in the same manner as in Example 2(1) above. The difference spectrum was obtained by subtracting the ACP spectrum and the HR2 peptide spectrum from the spectrum of the mixture.

[0068] Figure 7 shows the spectral diagrams of the mixture and difference spectra for four types of ACP (ACP21_EK, ACP21_QN, ACP26_EK, and ACP26_QN) (Figure 7-1: ACP21_EK; Figure 7-2: ACP21_QN; Figure 7-3: ACP26_EK; Figure 7-4: ACP26_QN). As can be seen in Figure 7, for the four types of ACP tested, negative peaks appeared at 208 nm and 222 nm in the difference spectrum as the amount of ACP added increased when mixed with the HR2 peptide. As a result, it was confirmed that interactions occurred between the HR2 domain and the four types of ACP, inducing an α-helix structure.

[0069] Furthermore, the helix content (%) was determined using the 222 nm CD spectrum value of each peptide. The results are shown in Table 5 below. This indicates that the helix was strongly induced by the binding of ACP to the HR2 domain.

[0070] [Table 5]

[0071] (2) Electrospray ionization mass spectrometry (ESI-MS) by infusion To investigate the interaction between four types of ACPs and HR2, mixtures of each ACP and HR2 domain peptide were subjected to ESI-MS analysis. The ACPs and HR2 domain peptides were mixed in a 1:1 molar ratio and dissolved in 5 mM Tris buffer (pH 8.0) and 50% v / v ethanol, adjusting the peptide concentrations of both HR2 and ACP to 40 μM. Measurements were performed by infusion of the samples using a quadrupole electric field Fourier transform mass spectrometer (Orbitrap Exploris 240; Thermo Fisher Scientific, Massachusetts, USA).

[0072] The mass spectra for ACP21_QN and ACP26_EK are shown in Figure 8 (Figure 8A: ACP21_QN; Figure 8B: ACP26_EK).

[0073] Regarding ACP21_QN, as shown in Figure 8A, a high peak was detected at m / z 1984.6104, z=4. Since the peak measured for a composition of HR2:ACP21_QN=1:2 was m / z 1984.8607, z=4, it was determined that this detected peak indicates a composition of HR2:ACP21_QN=1:2. In addition, a peak was observed at m / z 1940.3088, z=4. Since the measured value for a composition of HR2:ACP21_QN=2:1 was m / z 1939.8107, z=4, this peak represented a composition of HR2:ACP21_QN=2:1. Similarly, for ACP26_EK, peaks were detected at positions corresponding to the HR2:ACP26_EK=1:2 and HR2:ACP26_EK=2:1 compositions (Figure 8B). While naturally occurring HR2 molecules can form trimers, it was found that ACP can replace one or two HR2 molecules to form a complex with them.

[0074] (3) Structural analysis based on molecular dynamics calculations Molecular dynamics calculations ("MD calculations") were performed on a peptide molecule, approximately 10,000 water molecules, and approximately 30 Na molecules. + and Cl -Density 0.9 g / cm³ 3 The calculations were performed on a cubic cell. The initial peptide structure was prepared from the predicted structure output by AlphaFold2. All calculations were performed using Winmostar V11 and followed periodic boundary conditions.

[0075] The cutoff distance for non-covalent bonds was set to 1.2 nm. Calculations were performed in the following order: energy minimization calculation, equilibration calculation of a 10 ps NVT ensemble, and a 50 ps NPT ensemble. The energy minimization calculation was performed with a maximum of 20,000 steps and a convergence criterion of 100 kJ / mol / nm. The temperature was fixed at 300 K using a Nose-Hoover thermostat, and the pressure was fixed at 1 atm using a Parrinello-Rahman barostat. AMBER03 was used for the force field for proteins, SPC / E for water molecules, and GAFF for other molecules, and all calculations were performed under a time constant of 1 fs. Based on the three-dimensional structure after simulation, the interactions between peptides were analyzed by visualization using Discovery Studio 2021.

[0076] Figure 9 shows the three-dimensional structure of the peptide visualized by structural analysis based on molecular dynamics calculations. Figure 9(a) shows the interaction structure of the HR2 domain excised from the natural spike protein (HR2+ACP0: the interaction that occurs when HR2 forms a helix bundle with HR1 in nature was analyzed. "ACP0" refers to the domain with which HR2 interacts in nature (i.e., HR1)), and (b) shows the structure after the interaction between HR2 and ACP21_EK (HR2_W+ACP21_EK_W). Furthermore, for each case, the combinations of amino acids that resulted in hydrophobic interactions are shown in Table 6 below.

[0077] [Table 6]

[0078] A comparison of Figures 9(a) and (b) shows that ACP21_EK packs more tightly with HR2 through more hydrophobic interactions compared to the natural spike protein. Furthermore, while the analyzed HR2 domain (positions 1178-1197 of the amino acid sequence of SEQ ID NO: 1) was confirmed to bind antiparallel to a portion of HR1 (positions 929-942 of the amino acid sequence of SEQ ID NO: 1), ACP21_EK was shown to bind in parallel to the same HR2 domain, resulting in more hydrophobic interactions (Table 6). This analysis confirmed that ACP can bind to HR2 in an α-helix structure.

[0079] [Example 4: Evaluation of ACP's infection-inhibiting activity] The effects of ACP on viral infection of cells were evaluated, specifically its infection inhibitory activity and cytotoxicity. For this evaluation, human osteosarcoma-derived osteoblast-like cell lines, HOS cells (obtained from the National Institute of Infectious Diseases), were used. The virus used was SARS-CoV-2 pseudovirus (pCA-SARS-CoV-2 S D614G (SARS-CoV-2 S expression plasmid), psPAX2-IN / HiBiT (lentiviral vector packaging plasmid), and pWPI-Luc2 (luciferase-expressing lentiviral plasmid) were introduced into 293T cells as described in PLoS ONE 17(10): e0274829). Infection inhibitory activity and cytotoxicity were evaluated using the procedure described below.

[0080] (1)Single-cycle infection assay Cells were plated and left to stand overnight. Meanwhile, the virus and ACP were incubated at 37°C for 1 hour. After incubation, a mixture of the virus and ACP was added to the cells and incubated at 37°C for 48 hours. Subsequently, luciferase luminescence was measured for 10 seconds.

[0081] (2) Cytotoxicity test Cells were plated and left to stand overnight. ACP was added to these cells and they were left to stand at 37°C for 48 hours. Next, a reagent containing WST-1 was added and they were left to stand at 37°C for 15-60 minutes. After that, the absorbance at 450 nm (absorbance of WST-1 formazan) was measured.

[0082] (3) Results Table 7 shows the results of the infection inhibitory activity evaluation (IC). 50 ) and cytotoxicity evaluation results (CC 50 ) indicates.

[0083] [Table 7]

[0084] Both ACP21_EK and ACP21_QN inhibited viral infection at a low concentration of 15 μM. Furthermore, these peptides did not cause cell toxicity even at the maximum concentration (100 μM) used in this evaluation. Infection inhibition effects were also observed when using ACP26_EK and ACP26_QN. In this evaluation, cytotoxicity occurred at high concentrations of ACP26_EK and ACP26_QN.

[0085] It should be noted that the present invention is not limited to the embodiments and examples described above, and various modifications are possible within the scope of the claims. Embodiments obtained by appropriately combining the technical means disclosed in different embodiments are also included within the technical scope of the present invention. Furthermore, all academic and patent documents mentioned herein are incorporated herein by reference.

Claims

1. A peptide or a salt thereof that binds to the HR2 domain in the S2 region of the spike protein of the novel coronavirus SARS-CoV-2, wherein the number of amino acid residues is 50 or less.

2. The peptide or salt thereof according to claim 1, which targets the region containing the amino acid sequence NIQKEIDRLNEVAKNLNESL (SEQ ID NO: 2) from positions 1178 to 1197 of the amino acid sequence of SEQ ID NO:

1.

3. A peptide or salt thereof according to claim 1, which forms an α-helix.

4. The peptide or a salt thereof according to claim 1, which binds to the HR domain via hydrophobic interaction.

5. The peptide according to claim 1, wherein the peptide comprises an amino acid sequence represented by the following formula (I) or (II): (I) ALREQLERLLRQLQELX 1 RX 2 L (Sequence ID 3) (II) ALREQLERLLRQLQELX 1 RX 2 LRELQR (Sequence ID 4) (X 1 and X 2 Either one is a positively charged amino acid and the other is a negatively charged amino acid, or X 1 and X 2 This refers to a combination of the same or different uncharged amino acids.

6. The peptide according to claim 5 or a salt thereof, wherein the peptide comprises any of the following amino acid sequences (1) to (4). (1) ALREQLERLLRQLQELERKL (Sequence ID 5) (2) ALREQLERLLRQLQELQRNL (Sequence ID 6) (3) ALREQLERRLQLQELERKLRELQR (Sequence ID 7) (4) ALREQLERLLRQLQELQRNLRELQR (Sequence ID 8)

7. The peptide according to claim 6 or a salt thereof, wherein the peptide comprises any of the following amino acid sequences (1w) to (4w). (1w)ALREQLERLLRQLQELERKLW (Sequence ID 9) (2w)ALREQLERLLRQLQELQRNLW (Sequence ID 10) (3w)ALREQLERLLRQLQELERKLRELQRW (Sequence ID 11) (4w)ALREQLERLLRQLQELQRNLRELQRW (Sequence ID 12)

8. A novel coronavirus infection inhibitor containing the peptide or a salt thereof according to any one of claims 1 to 7.

9. A composition for the treatment of COVID-19 containing the peptide or a salt thereof according to any one of claims 1 to 7.